Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
Lithium is the first-line treatment for bipolar disorder (BD), but there is a large variation in response rate and adverse effects. Although the molecular effects of lithium have been studied extensively, the specific mechanisms of action remain unclear. In particular, the molecular changes underlying lithium adverse effects are little known. Multiple linear regression analyses of lithium serum concentrations and global gene expression levels in whole blood were carried out using a large case-control sample (n = 1450). Self-reported adverse effects of lithium were assessed with the "Udvalg for Kliniske Undersøgelser" (UKU) adverse effect rating scale, and regression analysis was used to identify significant associations between lithium-related genes and six of the most common adverse effects. Serum concentrations of lithium were significantly associated with the expression levels of 52 genes (FDR < 0.01), largely replicating previous results. We found 32 up-regulated genes and 20 down-regulated genes in lithium users compared to non-users. The down-regulated gene set was enriched for several processes related to the translational machinery. Two adverse effects were significantly associated (p < 0.01) with three or more lithium-associated genes: tremor (FAM13A-AS1, FAR2, ITGAX, RWDD1, and STARD10) and xerostomia (ANKRD13A, FAR2, RPS8, and RWDD1). The adverse effect association with the largest effect was between CAMK1D expression and nausea/vomiting. These results suggest putative transcriptional mechanisms that may predict lithium adverse effects, and could thus have a large potential for informing clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Progress in neuro-psychopharmacology & biological psychiatry - 112(2022) vom: 10. Jan., Seite 110408 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Krull, Florian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2022 Date Revised 14.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pnpbp.2021.110408 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328650676 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328650676 | ||
| 003 | DE-627 | ||
| 005 | 20231225203403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pnpbp.2021.110408 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328650676 | ||
| 035 | |a (NLM)34320404 | ||
| 035 | |a (PII)S0278-5846(21)00167-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Krull, Florian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2022 | ||
| 500 | |a Date Revised 14.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Lithium is the first-line treatment for bipolar disorder (BD), but there is a large variation in response rate and adverse effects. Although the molecular effects of lithium have been studied extensively, the specific mechanisms of action remain unclear. In particular, the molecular changes underlying lithium adverse effects are little known. Multiple linear regression analyses of lithium serum concentrations and global gene expression levels in whole blood were carried out using a large case-control sample (n = 1450). Self-reported adverse effects of lithium were assessed with the "Udvalg for Kliniske Undersøgelser" (UKU) adverse effect rating scale, and regression analysis was used to identify significant associations between lithium-related genes and six of the most common adverse effects. Serum concentrations of lithium were significantly associated with the expression levels of 52 genes (FDR < 0.01), largely replicating previous results. We found 32 up-regulated genes and 20 down-regulated genes in lithium users compared to non-users. The down-regulated gene set was enriched for several processes related to the translational machinery. Two adverse effects were significantly associated (p < 0.01) with three or more lithium-associated genes: tremor (FAM13A-AS1, FAR2, ITGAX, RWDD1, and STARD10) and xerostomia (ANKRD13A, FAR2, RPS8, and RWDD1). The adverse effect association with the largest effect was between CAMK1D expression and nausea/vomiting. These results suggest putative transcriptional mechanisms that may predict lithium adverse effects, and could thus have a large potential for informing clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Bipolar disorder | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a Lithium | |
| 650 | 4 | |a Microarray analysis | |
| 650 | 4 | |a Psychiatric disorders | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a FAM13A protein, human |2 NLM | |
| 650 | 7 | |a GTPase-Activating Proteins |2 NLM | |
| 650 | 7 | |a Lithium |2 NLM | |
| 650 | 7 | |a 9FN79X2M3F |2 NLM | |
| 650 | 7 | |a CAMK1D protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.17 |2 NLM | |
| 650 | 7 | |a Calcium-Calmodulin-Dependent Protein Kinase Type 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.17 |2 NLM | |
| 700 | 1 | |a Akkouh, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Bettella, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Athanasiu, Lavinia |e verfasserin |4 aut | |
| 700 | 1 | |a Smeland, Olav B |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connell, Kevin S |e verfasserin |4 aut | |
| 700 | 1 | |a Brattbakk, Hans-Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Steen, Vidar M |e verfasserin |4 aut | |
| 700 | 1 | |a Steen, Nils Eiel |e verfasserin |4 aut | |
| 700 | 1 | |a Djurovic, Srdjan |e verfasserin |4 aut | |
| 700 | 1 | |a Andreassen, Ole A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progress in neuro-psychopharmacology & biological psychiatry |d 1985 |g 112(2022) vom: 10. Jan., Seite 110408 |w (DE-627)NLM012970751 |x 1878-4216 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2022 |g day:10 |g month:01 |g pages:110408 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pnpbp.2021.110408 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2022 |b 10 |c 01 |h 110408 | ||